{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:46:49Z","timestamp":1792576009370,"version":"4.5.0"},"reference-count":31,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The efficacy of checkpoint inhibitors (e.g., pembrolizumab) in head and neck squamous cell carcinoma (HNSCC) is limited by cancer-associated fibroblasts (CAFs). This randomized, double-blind, placebo-controlled, phase II trial (NCT05323656) evaluated the efficacy and safety of the reactive oxygen species inhibitor setanaxib with pembrolizumab in patients with CAF-rich HNSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Participants (\u226518 years) with recurrent or metastatic HNSCC with CAF tumor levels \u22655% received setanaxib (800 mg orally twice a day) or placebo for \u2264105 weeks, plus intravenous pembrolizumab (200 mg every 3 weeks). The primary outcome was the best percentage change from baseline in tumor size. Secondary outcomes included progression-free survival (PFS), overall survival (OS), and changes in tumor levels of CAFs; cluster of differentiation 8 (CD8)+ tumor-infiltrating lymphocytes (TIL); and forkhead box P3 (FOXP3)+ regulatory T cells at week 9.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty-five participants (setanaxib, n = 27; placebo, n = 28) were treated. Least squares (LS) mean (standard error) best percentage changes in tumor size from baseline values were \u22127.9% (9.3%; setanaxib) and \u221212.9% {9%; placebo; LS mean difference [80% confidence interval (CI)], 5.1 (\u221211.9 to 22); P = 0.7008}. PFS hazard ratio (HR; 80% CI) was 0.58 (0.38\u20130.89), favoring setanaxib [P = 0.1023 (threshold &amp;lt; 0.2)]. OS HR (80% CI) was 0.45 (0.24\u20130.85), also favoring setanaxib (P = 0.1057). Transcriptomic analyses identified a significant increase in CD8+ TILs with setanaxib (P = 0.037), but not placebo. There were 33 serious adverse events (16 setanaxib and 17 placebo), leading to four deaths (all placebo).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These improvements in PFS, OS, and CD8+ TILs can guide further setanaxib research in patients with solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Early data suggest that for patients with cancers rich in fibroblasts, adding setanaxib to existing therapy could improve treatment response. This study suggests that combining pembrolizumab with setanaxib improved survival measures in patients with fibroblast-rich recurrent and\/or metastatic head and neck cancer. These findings support further evaluation of setanaxib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0422","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:44:57Z","timestamp":1790876697000},"page":"2463-2474","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-7019","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Fayette","sequence":"first","affiliation":[{"name":"1Medicine Department, Centre L\u00e9on B\u00e9rard, Lyon, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3832-7335","authenticated-orcid":false,"given":"Gareth J.","family":"Thomas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 2 School of Cancer Sciences, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-812X","authenticated-orcid":false,"given":"Amaury","family":"Daste","sequence":"additional","affiliation":[{"name":"3Medical Oncology, CHU Bordeaux \u2013 H\u00f4pital St. Andr\u00e9, Bordeaux, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1117-9578","authenticated-orcid":false,"given":"Maciej","family":"Rotarski","sequence":"additional","affiliation":[{"name":"4Oncology Department, Centre Oncologie du Pays Basque, Bayonne, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-9808","authenticated-orcid":false,"given":"Beatriz","family":"Castelo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s1q0w69","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario La Paz 5 Medical Oncology, , Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7365-9629","authenticated-orcid":false,"given":"Antonio","family":"Rullan","sequence":"additional","affiliation":[{"name":"6Head and Neck Unit, The Royal Marsden Hospital \u2013 Chelsea, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1536-3472","authenticated-orcid":false,"given":"Aaron","family":"Levine","sequence":"additional","affiliation":[{"name":"7Statistics Department, Calliditas Therapeutics AB, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4618-421X","authenticated-orcid":false,"given":"Richard","family":"Philipson","sequence":"additional","affiliation":[{"name":"8Clinical Department, Calliditas Therapeutics AB, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7588-0044","authenticated-orcid":false,"given":"Benjamin H.","family":"Jenkins","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01ryk1543","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Southampton 2 School of Cancer Sciences, , Southampton, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[{"name":"6Head and Neck Unit, The Royal Marsden Hospital \u2013 Chelsea, London, United Kingdom."},{"id":[{"id":"https:\/\/ror.org\/043jzw605","id-type":"ROR","asserted-by":"publisher"}],"name":"The Institute of Cancer Research 9 Division of Radiotherapy and Imaging, , Royal Marsden, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"2026102105313829300_bib1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/path.2830","article-title":"Stromal features are predictive of disease mortality in oral cancer patients","volume":"223","author":"Marsh","year":"2011","journal-title":"J Pathol"},{"key":"2026102105313829300_bib2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/jnci\/djx121","article-title":"Targeting the myofibroblastic cancer-associated fibroblast phenotype through inhibition of NOX4","volume":"110","author":"Hanley","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2026102105313829300_bib3","doi-asserted-by":"publisher","first-page":"131737","DOI":"10.1155\/2014\/131737","article-title":"Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic disease","volume":"2014","author":"Sampson","year":"2014","journal-title":"Biomed Res Int"},{"key":"2026102105313829300_bib4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13058-022-01548-6","article-title":"Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction","volume":"24","author":"Mir","year":"2022","journal-title":"Breast Cancer Res"},{"key":"2026102105313829300_bib5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"2026102105313829300_bib6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026102105313829300_bib7","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat Commun"},{"key":"2026102105313829300_bib8","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","article-title":"NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors","volume":"80","author":"Ford","year":"2020","journal-title":"Cancer Res"},{"key":"2026102105313829300_bib9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"2026102105313829300_bib10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","article-title":"Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy","volume":"10","author":"Dominguez","year":"2020","journal-title":"Cancer Discov"},{"key":"2026102105313829300_bib11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"2026102105313829300_bib12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026102105313829300_bib13","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1001\/jamaoncol.2017.0973","article-title":"Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques","volume":"3","author":"Leeman","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026102105313829300_bib14","volume-title":"Prescribing information","author":"KEYTRUDA\u00ae (pembrolizumab) injection","year":"2024"},{"key":"2026102105313829300_bib15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026102105313829300_bib16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40265-023-01835-2","article-title":"Treating head and neck cancer in the age of immunotherapy: a 2023 update","volume":"83","author":"Bhatia","year":"2023","journal-title":"Drugs"},{"key":"2026102105313829300_bib17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/jcmm.17649","article-title":"Pre-clinical evidence of a dual NADPH oxidase 1\/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis","volume":"27","author":"Thannickal","year":"2023","journal-title":"J Cell Mol Med"},{"key":"2026102105313829300_bib18","doi-asserted-by":"publisher","first-page":"S1468","DOI":"10.1002\/hep.32697","article-title":"An open-label, phase 1 study to evaluate the pharmacokinetics (PK) and drug-drug interactions of setanaxib tablets in healthy adults","volume":"2022","author":"Szyndralewiez","year":"2022","journal-title":"Hepatology"},{"key":"2026102105313829300_bib19","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver Int"},{"key":"2026102105313829300_bib20","doi-asserted-by":"publisher","first-page":"e0057","DOI":"10.1097\/HC9.0000000000000057","article-title":"Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial","volume":"7","author":"Jones","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026102105313829300_bib21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026102105313829300_bib22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026102105313829300_bib23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","article-title":"Intermittent PI3K\u03b4 inhibition sustains anti-tumour immunity and curbs irAEs","volume":"605","author":"Eschweiler","year":"2022","journal-title":"Nature"},{"key":"2026102105313829300_bib24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026102105313829300_bib25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"2026102105313829300_bib26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12943-024-02191-9","article-title":"Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response","volume":"24","author":"Jenkins","year":"2025","journal-title":"Mol Cancer"},{"key":"2026102105313829300_bib27","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","article-title":"Design issues of randomized phase II trials and a proposal for phase II screening trials","volume":"23","author":"Rubinstein","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026102105313829300_bib28","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2026102105313829300_bib29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"2026102105313829300_bib30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","article-title":"Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis","volume":"4","author":"Ritchie","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026102105313829300_bib31","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/cac2.12480","article-title":"Intratumoral CD103+ CD8+ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma","volume":"43","author":"Ren","year":"2023","journal-title":"Cancer Commun (Lond)"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0422\/3834950\/crc-26-0422.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2463\/3840484\/crc-26-0422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2463\/3840484\/crc-26-0422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:31:43Z","timestamp":1792575103000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2463\/789474\/Setanaxib-Added-to-Pembrolizumab-for-Fibroblast"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0422","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34731645","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731666","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731633","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731654","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731639","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731648","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731636","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731660","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731663","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34731651","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}